Ubiquitin, a small but mighty protein, is present in nearly all human tissues and plays a crucial role in controlling cellular processes. However, when Ub signalling goes awry, it has been associated with various diseases.
The Feltham laboratory is a place where cutting-edge research is being conducted to unravel the mysteries of how Ub signalling becomes disrupted.
In the Feltham laboratory, we’re all about finding new and improved ways to fight chronic inflammation-driven diseases like cancer and Parkinson’s disease. We focus on discovering and targeting “undruggable” proteins that play a critical role in these diseases, using a cutting-edge technology; PROTACs.
PROTACs are a game-changer in the world of therapeutics, allowing us to target proteins that were previously considered impossible to tackle.
Our approach is simple but effective: identify, validate, and target. We screen for new disease proteins, then use the latest tech to make sure they’re worth designing drugs against. Finally, we use PROTACs to target those proteins, removing them entirely from the equation.
We’re making incredible strides towards a future where chronic inflammation can be cooled down and patients can live better lives. Together, we can make a real difference in the fight against chronic diseases.
The Feltham laboratory’s mission is to develop innovative therapies for chronic inflammation-driven diseases like cancer and Parkinson’s. By identifying and targeting “undruggable” proteins using cutting-edge technology like PROTACs, we aim to eliminate these proteins entirely, paving the way for new treatments for patients. We’re committed to making a difference in the fight against chronic diseases, and our work is driven by a passion for uncovering the secrets of Ubiquitin signalling and its role in disease.
The Feltham laboratory’s work has significantly contributed to scientific knowledge by advancing our understanding of Ubiquitin signalling and its role in cancer and inflammatory diseases. Together we have developed new target validation technologies, novel mouse models and innovative screening platforms to target “undruggable” proteins using PROTAC technology. The lab’s research has helped to pave the way for the development of new therapies for patients with these diseases. The Feltham lab’s work has the potential to make a significant impact on the community more broadly by improving the lives of those affected by chronic inflammation-driven diseases.
The projects undertaken in my lab are some of the most exciting in the ubiquitin field.
We utilise diverse techniques from basic biochemistry, for example cloning and western blotting, to complex cellular and in vivo systems, for example CRISPR/Cas9 targeting and laboratory models of disease.
Specifically, we focus our efforts on identifying, characterising and targeting E3 ubiquitin ligases using two main approaches:
1. Cell-based screens to identify critical E3 ligases that regulate inflammatory signalling.
2. PROTAC-based targeting strategies (dTAG) to validate E3 ligases as therapeutic targets.
Ultimately this work will help in our understanding of how ubiquitin signalling is deregulated in cancer and chronic inflammatory disease to aid in the development of new therapies
My team comprises enthusiastic, motivated and driven scientists who are keen to learn and are excited about our research questions.
We collaborate extensively within WEHI to maximise our research output and to rapidly achieve our research goals.